<p>Omeros（納斯達克代碼：OMER - 獲取免費報告）於週四發佈了季度財報。這家生物製藥公司報告本季度每股收益為（$0.19），超出市場共識預期的（$0.58）$0.39，Zacks 報道。</p>
<h2>Omeros 股價上漲 25.3%</h2>
<p>週五午盤交易中，OMER 股票上漲$1.59，達到$7.87。該公司的股票交易量為 4,798,833 股，而其平均交易量為 1,620,257 股。Omeros 的 12 個月最低價為$2.95，最高價為$13.60。該公司的 50 日移動平均價格為$5.71，200 日移動平均價格為$4.59。公司的市值為 5.356 億美元，市盈率為-3.73，貝塔值為 2.40。</p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者最近增加或減少了對 OMER 的持股。Acadian Asset Management LLC 在第一季度購買了 Omeros 的新股份，價值$357,000。XTX Topco Ltd 在第二季度購買了 Omeros 的新股份，價值$191,000。Invesco Ltd.在第二季度增加了對 Omeros 的持股 34.1%。Invesco Ltd.目前擁有 116,688 股該生物製藥公司的股票，價值$350,000，此前在上個季度又購買了 29,644 股。Marshall Wace LLP 在第二季度將其在 Omeros 的持股增加了 15.1%。Marshall Wace LLP 目前擁有 741,376 股該生物製藥公司的股票，價值$2,224,000，此前在該期間又購買了 97,224 股。最後，Sei Investments Co.在第二季度購買了 Omeros 的新股份，價值約$40,000。48.79% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些研究公司最近對 OMER 發表了看法。Needham &amp; Company LLC 在 10 月 15 日的研究報告中重申了對 Omeros 股票的 “持有” 評級。Wall Street Zen 在 9 月 20 日的研究報告中將 Omeros 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Omeros 股票的 “賣出（d-）” 評級。D. Boral Capital 在週五的研究報告中重申了 “買入” 評級，並對 Omeros 股票設定了$36.00 的目標價。最後，HC Wainwright 在 10 月 15 日的報告中將 Omeros 的目標價從$9.00 上調至$20.00，並給予該股票 “買入” 評級。一位分析師對該股票給予了強烈買入評級，兩位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為$33.67。</p>
<p><strong>查看我們最新的 OMER 股票報告</strong></p>
<h2>Omeros 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Omeros Corporation 是一家臨牀階段的生物製藥公司，發現、開發和商業化小分子和蛋白質治療藥物，以及針對免疫疾病的孤兒適應症，包括補體介導的疾病、癌症以及成癮和強迫性障礙。該公司正在開發的產品包括 Narsoplimab（OMS721/MASP-2），該藥物已完成針對造血幹細胞移植相關血栓性微血管病（TA-TMA）的關鍵試驗；目前正在進行針對免疫球蛋白 A 腎病（IgAN）的第三階段臨牀試驗；以及針對 COVID-19 的第二階段臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比 Omeros 更好</li>
<li>價值投資：在 2022 年這是一個好策略嗎？提示：永遠</li>
<li>Jefferies 告訴 NVIDIA 讓位，選擇 Broadcom 作為頂級半導體股票</li>
<li>NYSE 股票為投資者提供多種優質選擇</li>
<li>Fiserv 從未這樣做過——這是一個絕對的買入嗎？</li>
<li>債券市場假期是什麼？如何投資和交易</li>
<li>Eli Lilly 與特朗普達成協議：為什麼自那以來股價上漲了 10%</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg"/></p>
<h2>你現在應該投資$1,000 在 Omeros 嗎？</h2>
<p>在你考慮 Omeros 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Omeros 並不在名單上。</p>
<p>雖然 Omeros 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

奧麥羅制藥

<p>Omeros Corporation 報告了季度收益，超出預期，每股收益為（$0.19），而預期為（$0.58）。股價上漲 25.3%，達到$7.87，交易量增加。機構投資者調整了他們的持股，分析師的評級各不相同，普遍目標價為$33.67。Omeros 開發針對免疫疾病的治療藥物，並推進多個臨牀試驗</p>

<p>Omeros (NASDAQ:OMER - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.39, Zacks reports.</p>
<div class="lb-trans"><p>Omeros（納斯達克代碼：OMER - 獲取免費報告）於週四發佈了季度財報。這家生物製藥公司報告本季度每股收益為（$0.19），超出市場共識預期的（$0.58）$0.39，Zacks 報道。</p>
</div><h2>Omeros Trading Up 25.3%</h2>
<div class="lb-trans"><h2>Omeros 股價上漲 25.3%</h2>
</div><p>OMER stock traded up $1.59 during mid-day trading on Friday, reaching $7.87. The company's stock had a trading volume of 4,798,833 shares, compared to its average volume of 1,620,257. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60. The business's 50 day moving average price is $5.71 and its 200 day moving average price is $4.59. The company has a market cap of $535.60 million, a price-to-earnings ratio of -3.73 and a beta of 2.40.</p>
<div class="lb-trans"><p>週五午盤交易中，OMER 股票上漲$1.59，達到$7.87。該公司的股票交易量為 4,798,833 股，而其平均交易量為 1,620,257 股。Omeros 的 12 個月最低價為$2.95，最高價為$13.60。該公司的 50 日移動平均價格為$5.71，200 日移動平均價格為$4.59。公司的市值為 5.356 億美元，市盈率為-3.73，貝塔值為 2.40。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in OMER. Acadian Asset Management LLC bought a new stake in Omeros during the first quarter worth $357,000. XTX Topco Ltd bought a new stake in shares of Omeros during the 2nd quarter worth $191,000. Invesco Ltd. boosted its holdings in shares of Omeros by 34.1% in the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company's stock worth $350,000 after buying an additional 29,644 shares during the last quarter. Marshall Wace LLP grew its position in Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock valued at $2,224,000 after buying an additional 97,224 shares during the period. Finally, Sei Investments Co. purchased a new stake in Omeros during the second quarter worth about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對 OMER 的持股。Acadian Asset Management LLC 在第一季度購買了 Omeros 的新股份，價值$357,000。XTX Topco Ltd 在第二季度購買了 Omeros 的新股份，價值$191,000。Invesco Ltd.在第二季度增加了對 Omeros 的持股 34.1%。Invesco Ltd.目前擁有 116,688 股該生物製藥公司的股票，價值$350,000，此前在上個季度又購買了 29,644 股。Marshall Wace LLP 在第二季度將其在 Omeros 的持股增加了 15.1%。Marshall Wace LLP 目前擁有 741,376 股該生物製藥公司的股票，價值$2,224,000，此前在該期間又購買了 97,224 股。最後，Sei Investments Co.在第二季度購買了 Omeros 的新股份，價值約$40,000。48.79% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research firms have recently weighed in on OMER. Needham &amp; Company LLC restated a &#34;hold&#34; rating on shares of Omeros in a research note on Wednesday, October 15th. Wall Street Zen upgraded shares of Omeros from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, September 20th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Omeros in a report on Wednesday, October 8th. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $36.00 price target on shares of Omeros in a research note on Friday. Finally, HC Wainwright upped their target price on Omeros from $9.00 to $20.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $33.67.</p>
<div class="lb-trans"><p>一些研究公司最近對 OMER 發表了看法。Needham &amp; Company LLC 在 10 月 15 日的研究報告中重申了對 Omeros 股票的 “持有” 評級。Wall Street Zen 在 9 月 20 日的研究報告中將 Omeros 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Omeros 股票的 “賣出（d-）” 評級。D. Boral Capital 在週五的研究報告中重申了 “買入” 評級，並對 Omeros 股票設定了$36.00 的目標價。最後，HC Wainwright 在 10 月 15 日的報告中將 Omeros 的目標價從$9.00 上調至$20.00，並給予該股票 “買入” 評級。一位分析師對該股票給予了強烈買入評級，兩位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為$33.67。</p>
</div><p><strong>View Our Latest Stock Report on OMER</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 OMER 股票報告</strong></p>
</div><h2>Omeros Company Profile</h2>
<div class="lb-trans"><h2>Omeros 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.</p>
<div class="lb-trans"><p>Omeros Corporation 是一家臨牀階段的生物製藥公司，發現、開發和商業化小分子和蛋白質治療藥物，以及針對免疫疾病的孤兒適應症，包括補體介導的疾病、癌症以及成癮和強迫性障礙。該公司正在開發的產品包括 Narsoplimab（OMS721/MASP-2），該藥物已完成針對造血幹細胞移植相關血栓性微血管病（TA-TMA）的關鍵試驗；目前正在進行針對免疫球蛋白 A 腎病（IgAN）的第三階段臨牀試驗；以及針對 COVID-19 的第二階段臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Omeros</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Jefferies Tells NVIDIA to Step Aside, Picks Broadcom as Top Semiconductor Stock</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Fiserv Has NEVER Done This Before—Is It a Screaming Buy?</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Omeros 更好</li>
<li>價值投資：在 2022 年這是一個好策略嗎？提示：永遠</li>
<li>Jefferies 告訴 NVIDIA 讓位，選擇 Broadcom 作為頂級半導體股票</li>
<li>NYSE 股票為投資者提供多種優質選擇</li>
<li>Fiserv 從未這樣做過——這是一個絕對的買入嗎？</li>
<li>債券市場假期是什麼？如何投資和交易</li>
<li>Eli Lilly 與特朗普達成協議：為什麼自那以來股價上漲了 10%</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OMER"/></p>
<h2>Should You Invest $1,000 in Omeros Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Omeros 嗎？</h2>
</div><p>Before you consider Omeros, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Omeros 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Omeros 並不在名單上。</p>
</div><p>While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Omeros 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

奧麥羅製藥（NASDAQ:OMER）公佈了財報，每股收益比預期高出 0.39 美元